Chia Nan University of Pharmacy & Science Institutional Repository:Item 310902800/34126
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 18268/20495 (89%)
Visitors : 8664816      Online Users : 943
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34126


    题名: Cytoplasmic, but not nuclear Nrf2 expression, is associated with inferior survival and relapse rate and response to platinum-based chemotherapy in non-small cell lung cancer
    作者: Chen, Ming-Jenn
    Lin, Po-Lin
    Wang, Lee
    Cheng, Ya-Min
    Chen, Chih-Yi
    Lee, Huei
    贡献者: Chi Mei Med Ctr, Dept Surg
    Chia Nan Univ Pharm & Sci, Dept Sports Management, Coll Leisure & Recreat Management
    Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery
    Chung Shan Med Univ, Dept Publ Hlth
    Natl Cheng Kung Univ, Dept Obstet & Gynecol, Coll Med
    Chung Shan Med Univ Hosp, Dept Surg
    关键词: NSCLC
    chemotherapeutic response
    cytoplasmic Nrf2
    prognosis
    日期: 2020
    上传时间: 2022-11-18 11:25:00 (UTC+8)
    出版者: Wiley
    摘要: Background Several studies have previously indicated that nuclear factor erythroid 2-related factor 2 (Nrf2) expression may promote tumor progression when the Keap1/Nrf2 pathway is activated, but few reports have demonstrated the role of cytoplasmic Nrf2 on tumorigenesis. Methods Immunohistochemistry was conducted to evaluate Nrf2 expression in 167 tumors from surgically-resected patients with non-small cell lung cancer (NSCLC). Univariate and multivariate analyses were performed to examine the association of Nrf2 expression with patients' prognosis. This study was conducted to examine the association of Nrf2 expression with tumor response to cisplatin-based chemotherapy. Results Among these tumors, 56 and 32 of 167 tumors expressed Nrf2 in the cytoplasm (34% for C+/N-) and in the cytoplasm/nucleus (19% for C+/N+), but not in the nucleus of tumor cells. Nrf2 was negatively expressed in the remainder of the tumor samples (C-/N-, 79 of 167, 47%). Univariate analysis indicated that patients with Nrf2 positive tumors (C+/N- plus C+/N+) had worse overall survival (OS), but not relapse-free survival (RFS) than with Nrf2 negative tumors (C-/N-). However, patients with C+/N- tumors possessed worse OS and RFS than those with Nrf2 negative tumors (C-/N-). Multivariate analysis further confirmed the prognostic significance of patients with Nrf2 positive and C+/N- tumors on OS and RFS, but not on RFS for patients with Nrf2 positive tumors. Patients with Nrf2 positive and C+/N- tumors were determined to more frequently have an unfavorable response to cisplatin-based chemotherapy than those with Nrf2 negative tumors. Conclusions Cytoplasmic Nrf2 expression might potentially be used to predict poor prognosis and unfavorable response to cisplatin-based chemotherapy in patients with NSCLC.
    關聯: Thoracic Cancer, v.11, n.7, pp.7
    显示于类别:[Dept. of Sports Management] Periodical Articles

    文件中的档案:

    档案 描述 大小格式浏览次数
    10.11111759-7714.13479.pdf3922KbAdobe PDF202检视/开启
    index.html0KbHTML762检视/开启


    在CNU IR中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback